• Hoa Q Nguyen, Jian Lin, Emi Kimoto, Ernesto Callegari, Susanna Tse, and R Scott Obach.
• Boehringer Ingelheim Pharmaceuticals Inc., Drug Metabolism and Pharmacokinetics Department, Ridgefield, Connecticut 06877. Electronic address: hoa_2.nguyen@boehringer-ingelheim.com.
• J Pharm Sci. 2017 Sep 1; 106 (9): 2758-2770.

AbstractThe aim of this study was to evaluate a strategy based on static and dynamic physiologically based pharmacokinetic (PBPK) modeling for the prediction of metabolite and parent drug area under the time-concentration curve ratio (AUCm/AUCp) and their PK profiles in humans using in vitro data when active transport processes are involved in disposition. The strategy was applied to losartan and its pharmacologically active metabolite carboxylosartan as test compounds. Hepatobiliary transport including transport-mediated uptake, canilicular and basolateral efflux, and metabolic clearance estimates were obtained from in vitro studies using human liver microsomes and sandwich-cultured hepatocytes. Human renal clearance of carboxylosartan was estimated from dog renal clearance using allometric scaling approach. All clearance mechanisms were mechanistically incorporated in a static model to predict the relative exposure of carboxylosartan versus losartan (AUCm/AUCp). The predicted AUCm/AUCp were consistent with the observed data following intravenous and oral administration of losartan. Moreover, the in vitro parameters were used as initial parameters in PBPK permeability-limited disposition models to predict the concentration-time profiles for both parent and its active metabolite after oral administration of losartan. The PBPK model was able to recover the plasma profiles of both losartan and carboxylosartan, further substantiating the validity of this approach.Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

40 keywords...

hide…